Dianthus Therapeutics
DNTH
54 hedge funds and large institutions have $125M invested in Dianthus Therapeutics in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 10 closing their positions.
441% more capital inflows, than outflows
Capital inflows: $85.8M | Capital outflows: $15.9M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
25.28% more ownership
Funds ownership: 41.13% → 66.41% (+25%)
6% more funds holding
Funds holding: 51 → 54 (+3)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
+$3.52M |
| 2 |
CC
Casdin Capital
New York
|
+$3.34M |
| 3 |
BlackRock
New York
|
+$3.28M |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$2.02M |
| 5 |
Anchor Capital Advisors
Boston,
Massachusetts
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.99M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$2.79M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.04M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.87M |
| 5 |
NC
Nexthera Capital
New York
|
-$1.8M |
DNTH Hedge Fund Activity: Q4 2018 in Review
54 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q4 2018, worth a combined $125M — down 23% from $162M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new DNTH positions and 10 closed out — a net gain of 4 holders — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $3.52M. The largest seller was VOYA Investment Management, exiting entirely with an estimated $2.99M sold.
- 54 institutional investors held Dianthus Therapeutics (DNTH) as of Q4 2018, up from 51 in Q3 2018.
- Funds reported $125M of Dianthus Therapeutics stock for Q4 2018, down 23% quarter-over-quarter.
- 14 funds opened new Dianthus Therapeutics positions in Q4 2018 and 10 closed out, a net change of +4 holders.
- The largest Dianthus Therapeutics buyer in Q4 2018 was Eventide Asset Management, an estimated $3.52M added.
- The largest Dianthus Therapeutics seller in Q4 2018 was VOYA Investment Management, an estimated $2.99M sold.
Based on aggregated 13F filings for Q4 2018.